HomeInsightsStock Comparison

Granules India Ltd vs Natco Pharma Ltd Stock Comparison

Granules India Ltd vs Natco Pharma Ltd Stock Comparison

Last Updated on: May 06, 2025

Key Highlights

  • The Latest Trading Price of Granules India Ltd is ₹ 454.15 as of 06 May 09:51.
  • The P/E Ratio of Granules India Ltd changed from 10.9 on March 2020 to 25.7 on March 2024 . This represents a CAGR of 18.71% over 5 yearsThe P/E Ratio of Natco Pharma Ltd changed from 20 on March 2020 to 12.3 on March 2024 . This represents a CAGR of -9.26% over 5 years.
  • The Market Cap of Granules India Ltd changed from ₹ 3650 crore on March 2020 to ₹ 10420 crore on March 2024 . This represents a CAGR of 23.34% over 5 yearsThe Market Cap of Natco Pharma Ltd changed from ₹ 9215 crore on March 2020 to ₹ 17042 crore on March 2024 . This represents a CAGR of 13.08% over 5 years.
  • The revenue of Granules India Ltd for the Dec '24 is ₹ 1143 crore as compare to the Sep '24 revenue of ₹ 969.87 crore. This represent the growth of 17.89% The revenue of Natco Pharma Ltd for the Dec '24 is ₹ 651.1 crore as compare to the Sep '24 revenue of ₹ 1434 crore. This represent the decline of -54.62%.
  • The ebitda of Granules India Ltd for the Dec '24 is ₹ 235.97 crore as compare to the Sep '24 ebitda of ₹ 206.57 crore. This represent the growth of 14.23% The ebitda of Natco Pharma Ltd for the Dec '24 is ₹ 215.1 crore as compare to the Sep '24 ebitda of ₹ 868.1 crore. This represent the decline of -75.22%.
  • The net profit of Granules India Ltd changed from ₹ 47.9 crore to ₹ 117.6 crore over 7 quarters. This represents a CAGR of 67.07% The net profit of Natco Pharma Ltd changed from ₹ 420.3 crore to ₹ 132.4 crore over 7 quarters. This represents a CAGR of -48.32% .
  • The Dividend Payout of Granules India Ltd changed from 5.72 % on March 2020 to 8.34 % on March 2024 . This represents a CAGR of 7.83% over 5 yearsThe Dividend Payout of Natco Pharma Ltd changed from 25.89 % on March 2020 to 13.01 % on March 2024 . This represents a CAGR of -12.86% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Granules India Ltd

  • Granules India Limited is a large-scale vertically integrated company founded in March 18th, 1991 manufacturing Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediate (PFI) and Finished Dosage (FD).
  • With a strong presence across all three vertical, the company has created a leadership position in the off-patent drugs segment along with ensuring a strong presence in first line of defense' products such as Paracetamol, Ibuprofen, Metformin and Guaifenesin.
  • The company has a global presence across over 80 countries servicing over 300 customers.
  • Granules India is the preferred supplier for some of the world's leading pharma branded and generics companies.
  • The company has one of largest PFI and single site FD facilities in the world.

About Natco Pharma Ltd

  • Natco Pharma Limited is a vertically integrated and R&D focused pharmaceutical company that specialises in development, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs).
  • The Company's focus is primarily on niche therapeutic areas and complex products.
  • It sells products in over 40 countries.
  • FDF products are sold in the United States, India, Europe and the rest of the world (RoW).
  • Natco's API products are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets such as Brazil, Europe and USA. In the API segment, Natco has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides. Natco Pharma is also engaged in contract manufacturing business, whereby the company undertakes selected contracts with pharmaceutical companies to manufacture and supply pharmaceutical products.

Granules India Ltd News Hub

News

Granules India completes acquisition of Swiss-based CDMO - Senn Chemicals AG

Granules India announced the successful closing of the acquisition of Senn Chemicals AG, a...

Read more

11 Apr 2025 10:15

News

Granules India allots 50,000 equity shares under ESOS

Granules India has allotted 50,000 equity shares under ESOS on 20 March 2025. Powered by C...

Read more

20 Mar 2025 19:46

News

Granules India Ltd Falls 3.02%

Granules India Ltd lost 3.02% today to trade at Rs 457.2. The BSE Healthcare index is down...

Read more

05 Mar 2025 09:30

News

Granules India announces cessation of Senior VP and Head - API Manufacturing and Operations

Granules India announced that Sethu Madhavan Sankaran, shall cease to be the Senior Manage...

Read more

28 Feb 2025 14:19

News

Granules India rises after board OKs to acquire 100% stake in Senn Chemicals AG

Senn Chemicals AG, a Swiss-based CDMO specializing in peptides. It develops and manufactur...

Read more

24 Feb 2025 12:26

News

Granules India's board OKs to acquire 100% stake in Senn Chemicals AG

Senn Chemicals AG, a Swiss-based CDMO specializing in peptides. It develops and manufactur...

Read more

22 Feb 2025 08:56

Natco Pharma Ltd News Hub

News

Natco Pharma update on launch of Risdiplam in India

Natco Pharma today updates on the legal proceedings on Risdiplam launch in India. The Comp...

Read more

08 Apr 2025 11:16

News

Natco Pharma Ltd up for fifth session

Natco Pharma Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 8...

Read more

07 Mar 2025 13:00

News

Natco Pharma Ltd soars 1.69%

Natco Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 837...

Read more

25 Feb 2025 13:05

News

Natco Pharma slips as Q3 PAT slides 38% YoY to Rs 132 cr

Profit before tax in Q3 FY25 stood at Rs 163.7 crore, down 36.13% as against Rs 256.3 cror...

Read more

13 Feb 2025 11:11

News

Natco Pharma Ltd drops for fifth straight session

Natco Pharma Ltd fell for a fifth straight session today. The stock is quoting at Rs 997, ...

Read more

13 Feb 2025 13:35

News

Natco Pharma Ltd leads losers in 'A' group

Orchid Pharma Ltd, Vijaya Diagnostic Centre Ltd, FDC Ltd and Aegis Logistics Ltd are among...

Read more

13 Feb 2025 15:00

SWOT Analysis Of Granules India Ltd

Strength

4

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Natco Pharma Ltd

Strength

4

S

Weakness

3

W

Opportunity

1

O

Threats

1

T

BlinkX Score for Granules India Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Natco Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Granules India Ltd and Natco Pharma Ltd

Which company has a larger market capitalization, Granules India Ltd or Natco Pharma Ltd?

Market cap of Granules India Ltd is 11,211 Cr while Market cap of Natco Pharma Ltd is 15,342 Cr

What are the key factors driving the stock performance of Granules India Ltd and Natco Pharma Ltd?

The stock performance of Granules India Ltd and Natco Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Granules India Ltd and Natco Pharma Ltd?

As of May 6, 2025, the Granules India Ltd stock price is INR ₹462.25. On the other hand, Natco Pharma Ltd stock price is INR ₹856.6.

How do dividend payouts of Granules India Ltd and Natco Pharma Ltd compare?

To compare the dividend payouts of Granules India Ltd and Natco Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions